Blog

VANCOUVER, British Columbia, November 03, 2021 (GLOBE NEWSWIRE) – Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developer of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds with a focus on the health and wellness sector is pleased to announce the appointment of management and communications consultancy Kydder Management Group Inc. (“Kydder Group”) to assist with government, regulatory, corporate and policy matters.

Driven by a desire to help transform Canada’s mental health regime, the Kydder Group is a regulatory communications company led by Principal and Founder Michael Kydd, advising some of the world’s best-known psychedelic therapy, research and biotech companies and advises associations around the world.

The Kydder Group is currently citing Canada’s first Memorandum of Regulatory Approval (MORA) to change Health Canada’s current regulations, hopefully leading to controlled legal access to psilocybin therapy for palliative and end-of-life Canadians. The company also leads a national coalition through the Canadian Psychedelic Association that focuses on Medical Assistance in the Death (MAID) and psychedelic therapy as a worthy option for end-of-life Canadians’ quality of life.

“The industry has an incredible responsibility to communicate the safety and efficacy of controlled substances to the highest and most stringent scientific and clinical standards,” says Kydd. “Bill Ciprick and the Optimi Health team have a remarkable experience exceeding these standards and they understand the importance of building trust and operational excellence with Health Canada and consumers. Your growing presence as a global leader in functional fungal growth and research into psychoactive formulations is something I am very excited about. “

The Kydder Group has been tasked with advising and overseeing many key activities including managing the ongoing relationship with Health Canada, completing the facility inspection process, future changes to the dealer license, reporting changes and trends in Health Canada policy, identification future sales and export opportunities as well as entry into future approval applications (e.g. approval for pharmaceutical companies).

Additional services include in-industry partnerships and connectivity and regulatory environment development, including participating with other key industry players in regulatory development, attending industry discussions / meetings with Health Canada on regulatory issues, future appearances before parliamentary committees, meetings with provincial governments, to study the socio-economic benefits of psychedelic therapies and products, and the development of SOPs (as needed).

Eventually, the Kydder Group will manage political advocacy, including meeting and organizing factory tours with political officials, staff and other influencers. Overall, consumer and regulatory measures are coordinated with Optimi Health’s communications providers to help manage the messaging strategy and tactics.

Bill Ciprick, CEO of Optimi Health, commented, “We are excited to welcome Michael and his team at this critical point in the growth of our company and the industry. Optimi is a passionate group of innovators in mushroom-based formulations. As we are at the forefront of an industry, we need to make sure our path is centered around the least resistance, which is achieved through communication and regulatory excellence. Today’s announcement is another positive step in unlocking the value of the psychedelic marketplace. “

On behalf of the Board of Directors,

Bill Ciprick
Managing Director
Optimi Health Corp.

ABOUT OPTIMI (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8 billion)
Optimi is developing a sophisticated mushroom brand that focuses on the health and wellness market. Using a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional mushroom products at its two 20,000 square foot facilities near completion in Princeton, British Columbia. To fully study the science of mushrooms, the company, through its wholly owned subsidiary Optimi Labs Inc, has a distributor license under the Canadian Narcotic Control Regulations that govern the ownership, distribution, sale, laboratory analysis, and research and development of psilocybin and psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with all applicable laws and regulations to ensure safe and superior Canadian mushroom production. Find out more at: https://optimihealth.ca/.

FOR FURTHER INFORMATION CONTACT:
Investor Relations
Email: [email protected]
Phone: +1 (778) 930-1321
Internet: https://optimihealth.ca/

FORWARD–LOOKING STATEMENTS
This press release contains forward-looking statements and forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and beliefs about future events. Any statements that express or discuss expectations, beliefs, plans, goals, assumptions or future events or performance (often, but not always, through the use of words or expressions such as “will likely result,” “is expected to.” “,” expects “,” continues “,” is expected “,” anticipated “,” believes “,” estimated “,” intends “,” plans “,” forecast “,” forecast “,” strategy “,” objective. ” “and” Outlook “) are not historical facts and may be forward-looking statements and contain estimates, assumptions and uncertainties that could cause actual results or results to differ materially from those expressed in such forward-looking statements. That these expectations will prove to be correct and one should not place undue reliance on such forward-looking statements in this press release apply only as of the date of this press release. In particular, and without limitation, this press release contains forward-looking statements regarding the Company’s potential listing on the Nasdaq, the dealer’s license application, activities to be conducted under the Company’s research exemption, and related psilocybin and psilocin-related business Optimis plans, focus and goals.

Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control and which could cause actual results and events to differ materially from those disclosed or implied in such statements forward-looking statements. These risks and uncertainties include the effects and progression of the COVID-19 pandemic and other factors that are listed under “Forward-Looking Statements” and “Risk Factors” in the company’s final prospectus dated February 12, 2021. Optimi assumes no obligation to update or revise any forward-looking statements as a result of new information, future events or otherwise, unless required by law to predict them all or to assess the effects of each of these factors or the extent to which any factor is affected or a combination of factors could cause results to differ materially from those in forward-looking statements. Press releases are expressly restricted in their entirety by this cautionary statement.

The CSE assumes no responsibility for the adequacy or accuracy of this press release.